Questions about how US President Donald Trump will shape FDA over the next four years may have driven agency staff to push out an unusually high number of guidances and regulations in recent weeks.
An end-of-administration document dump is typical as outgoing staff rush to complete projects before the new president arrives, but data suggests that FDA issued many more guidances in the waning...